Streetbeat News

Regulatory

DCTH

SCYX

SE

Delcath Systems, Inc. (DCTH) has received FDA approval for HEPZATO KIT™, causing its stock to surge by 138%. SCYNEXIS (SCYX) received a 'Buy' rating from Ladenburg Thalmann & Co., leading to a 37% increase in its stock. Sea Limited (SE) reported a GAAP EPS of $0.54, beating estimates by $0.08, but its revenue of $3.1B missed estimates by $150M, causing an 18% drop in its stock.

Portfolio Pulse from ryanfaloona@benzinga.com

August 15, 2023 | 12:35 pm

MOXC

Moxian, Inc. has regained compliance with NASDAQ's minimum bid price requirement. The company's common stock has maintained a closing bid price of $1.00 per share or more for at least 10 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:35 pm

SPY

The Export Price Index for July has increased by 0.7%, which is higher than the estimated 0.2% and a significant improvement from the previous month's -0.9%.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:31 pm

AAMC

DCTH

FXLV

SONM

Delcath Systems, Inc. (DCTH) shares surged 57.7% after the FDA approval of HEPZATO KIT™ for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Sonim Technologies, Inc. (SONM) rose 29.1% after reporting a 125% revenue increase in Q2. F45 Training Holdings Inc. (FXLV) fell 62.7% after announcing its intent to voluntarily delist and deregister its securities. Altisource Asset Management Corporation (AAMC) shares fell 61.3% after posting a wider Q2 loss.

Portfolio Pulse from Lisa Levin

August 15, 2023 | 12:17 pm

AKTX

Akari Therapeutics, Plc (NASDAQ:AKTX) has announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares from 1:100 to 1:2000, effective from August 17, 2023. The change is aimed at regaining compliance with the Nasdaq minimum bid price requirement. Deutsche Bank will manage the exchange of current ADSs for new ones. No fractional new ADSs will be issued, instead, fractional entitlements will be sold and the proceeds distributed to the applicable ADS holders.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 12:07 pm

CYBN

Cybin Inc. has been granted a U.S. patent for its proprietary deuterated psilocybin analog in the CYB003 program. The patent covers composition of matter claims and treatment methods until 2041. The company's intellectual property portfolio now includes 2 granted U.S. patents and over 50 pending patent applications across 6 patent families. CYB003 is currently being evaluated in a Phase 2 clinical trial for the treatment of major depressive disorder. The company expects to report topline Phase 2 efficacy data for CYB003 in Q3/Q4 2023.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 12:00 pm

CS

A Russian court has frozen the local assets of Credit Suisse, according to TASS. The details of the case and the potential impact on Credit Suisse's operations are not specified.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:46 am

SXTP

60 Degrees Pharmaceuticals has registered a Phase IIB study of Tafenoquine for the treatment of COVID-19 on ClinicalTrials.gov. The study is named ACLR8-LR.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:32 am

GLTO

Trading of Galecto's shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:26 am

DCTH

Delcath Systems announced that the FDA has approved its HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Following the announcement, the company's shares surged by 69% in premarket trading.

Portfolio Pulse from Charles Gross

August 15, 2023 | 11:12 am